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Aims: To clarify the prognosis and prognostic factors in pulmonary arterial hypertension (PAH) patients in real-
world medical practice in the Tokai area in Japan.
Mainmethods:Weconducted a retrospective, multicenter observational study. The data of 81 patients diagnosed
with Dana Point group 1 or 1′ PAH was collected from January 2005 to January 2013. The primary outcome was
all-cause death.
Key ﬁndings: The patients consisted of 34 cases of idiopathic PAH (IPAH), 28 of connective tissue-associated PAH
(CTD-PAH), 16 of congenital heart disease-associated PAH (CHD-PAH) and others. Mean age was 51 years and
mean observation period was 46 months. The systolic blood pressure (BPs) was 117 ± 23 mm Hg. Pericardial
effusion was observed in 27.0% of patients. The mean right atrial pressure (mRAP) was 10.2 ± 7.3 mm Hg.
In the univariate Cox regression analysis,WHO-FCS III & IV, a cardiac index (CI) b 2.5 L/min/m2, and the presence
of pericardial effusion at baseline were signiﬁcantly associated with all-cause death. In the multivariate analysis,
the pericardial effusion (HR 3.3, 95% CI 1.03–10.63, p= 0.04) andmRAP (HR 3.2, 95% CI 1.03–9.83, p= 0.04) or
CI b 2.5 L/min/m2 (HR 3.89, 95% CI 1.05–14.45, p = 0.04) were the independent predictors of mortality.
Signiﬁcance: The presence of pericardial effusion and mRAP or CI b 2.5 L/min/m2 at diagnosis indicated high
mortality.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/ .0/).3Introduction
Pulmonary arterial hypertension (PAH) is a disease with an ex-
tremely poor prognosis, which is characterized by elevated pulmonary
vascular resistance (PVR) leading to right heart failure or death (Benza
et al., 2012; McLaughlin and McGoon, 2006). Several studies to date
have described the prognosis of PAH and various prognosis-related fac-
tors (Benza et al., 2010; Humbert et al., 2010; Zhang et al., 2011). From
the 1980s to the 1990s, when there were no PAH-speciﬁc therapeutic
agents, the three year survival was less than 50% (Okada et al., 1999;
Dalonzo et al., 1991). PAH-speciﬁc therapeutic agents became available
in the late 1990s. However, whether or not the survival rate of PAH pa-
tientswith several etiology such as connective tissue disease associated-
PAH (CTD-PAH) and congenital heart disease associated-PAH (CHD-
PAH) is improved has not yet been proven (Benza et al., 2012).
The prevalence and prognosis of PAH may differ among countries.
For example, exposure to fenﬂuramine or dexfenﬂuramine is one
of the causes of PAH in Europe, whereas diet pills are rarely the causes
of PAH in Japan. Moreover, in many areas in Japan, cardiologists,o).
. This is an open access article underpulmonologists, or rheumatologists, who do not necessarily specialize
in treating PAH, often see PAH patients. However, there is limited recent
data available regarding the morbidity and mortality of patients with
PAH in real-world medical practice of Japan.
The predictive factors for mortality in PAH patients include a family
history of PAH, World Health Organization functional classes (WHO-
FCS) III and IV, renal dysfunction, a diminished six-minutewalk distance
(6MWD), an elevation of the mean right atrial pressure (mRAP), lower
carbon monoxide lung diffusing capacity (DLCO), the presence of peri-
cardial effusion, an elevated plasma brain natriuretic peptide (BNP)
level, low systolic blood pressure (BPs), and a high heart rate (HR)
(Benza et al., 2010). In particular, many studies have demonstrated
that the WHO-FC is a useful predictive factor (Benza et al., 2010;
Humbert et al., 2010; Nickel et al., 2012; McLaughlin et al., 2002). How-
ever, the WHO-FC evaluation varies according to attending physicians
(Taichman et al., 2009). Therefore, if another index that supplements
the WHO-FC is found, it would be useful for diagnosing and treating
PAH, especially for physicians who occasionally see PAH patients but
do not necessarily specialize in PAH.
This study aimed to elucidate the recent vital prognosis and relevant
prognostic factors in patients with PAH in the real-world medical
practice of Japan.the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/ .0/).3
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We conducted a retrospective, multicenter observational study of
PAH which involved 15 collaborating hospitals in the Tokai area in
Japan. The 81 consecutive patients diagnosed with Dana Point group 1
or 1′ PAHwere enrolled at these 15 hospitals (Nagoya university hospi-
tal and afﬁliated hospitals). The data collection periodwas from January
2005 to January 2013, and the observation start date was the day of the
diagnosis. The diagnosis was made by right heart catheterization (RHC)
in all patients. PAH was deﬁned as mean pulmonary arterial pressure
(mPAP) of ≥25 mmHg at rest and a pulmonary artery wedge pressure
of ≤15 mmHgmeasured during RHC. Data were extracted from medi-
cal records and by interviewing the attending physicians of relevant fa-
cilities. The extracted data included the data regarding the diagnosis,
age, gender, underlying disease, height, weight, WHO-FC, vital signs,
laboratory data, chest X-rays, results of the echocardiography and
cardiac catheterization, and cause of death. The causes of PAH were
classiﬁed into four groups: idiopathic PAH (IPAH), CTD-PAH, CHD-PAH
and others. Portopulmonary hypertension (PoPH), pulmonary capillary
hemangiomatosis (PCH) and pulmonary veno-occlusive disease
(PVOD) were classiﬁed as other causes. Scleroderma, polymyositis/
dermatomyositis and mixed connective tissue disease associated PAH
were classiﬁed as CTD-PAH. Ventricular septal defects, atrial septal
defects and patent ductus arteriosus were classiﬁed as CHD-PAH.
Baseline echocardiography and RHC were performed. Only Dana
Point classiﬁcation group 1 and 1′ PAH patients were included, and
other causes of PAH (WHO groups 2–5) were excluded. The treatment
of the PAHwas left to the discretion of the attending physicians. Pericar-
dial effusion was evaluated in the parasternal long- and short-axis view
of two-dimension echocardiography and graded absence or presence
(Eysmann et al., 1989). The presence of pericardial effusionwas deﬁned
as a distinct diastolic separation of the pericardial layers posterior to the
heart and excluded trace effusion where the pericardial space was
b5 mm in any view (Raymond et al., 2002).
The primary outcome was all-cause death: right heart failure, pneu-
monia, interstitial pneumonia and sudden death. The data of death was
all collected from medical records. The exact causes of death were re-
corded and veriﬁed through chart reviews. Relevant right heart failure
was deﬁned by using four criteria: lower extremity edema, jugular
vein distention, elevation of liver enzyme greater than three times,
anatomical right ventricular dilation and reduction of wall motion by
echocardiography. Pneumonia was deﬁned by inﬁltrative shadow in
chest X-ray, elevation of both C-reactive protein level and white blood
cell count. Interstitial pneumonia was deﬁned by interstitial pattern in
chest computed tomography and elevation of KL-6 level in laboratory
data. Sudden death was deﬁned by unknown death within 24 h.
Continuous variables were divided into two groups for the analysis
based on normal value, median or the level suggested from guidelines.
To further verify the correlation between the mRAP and pericardial
effusion, the mRAP was equally divided into three groups at 6 and
11mmHg. This studywas approved by the human research ethics com-
mittees of Nagoya University Hospital (No. 1157) and the individual
committee of each the afﬁliated hospital.
Statistical analysis
The patient characteristics at baseline are reported asmeans± stan-
dard deviation (SD) for continuous variables or proportions (percent-
ages) for categorical variables. Medical records of the 81 consecutive
patients with group 1 and 1′ PAH of the Dana Point classiﬁcation were
reviewed during the study periods. Mortality, morbidity and baseline
risk factors for mortality were examined.
We analyzed all the PAH patients diagnosed with RHC. Differences
between the two or three groups were assessed by the Chi-squared
test or the Kruskal–Wallis test for categorical variables, and t-test or
Welch test for continuous variables. The correlation between WHO-FCand pericardial effusion was assessed by the Cochran–Armitage test. A
Kaplan-Meier analysis was performed to estimate survival based on
each factor, and the statistical signiﬁcance of differences was compared
by the log-rank test. After testing the proportionality of the hazard, the
univariate and multivariate hazard ratios (HRs) were calculated by
using the Cox proportional hazard regression model to determine the
predictors of mortality with 95% conﬁdence intervals (95% CI). In the
multivariate analysis, either WHO-FC or the presence of pericardial
effusion was included because of their multicollinearity.
The selection of the independent variables was performed using
a multivariate forward step-wise selection method. Variables were
divided into two or three groups for the analysis as mentioned before.
Two-tailed p values ≤ 0.05 were considered to be statistically sig-
niﬁcant. All statistical analyses were performed using the SPSS18 soft-
ware program (SPSS Inc., Chicago, IL, USA).
Results
Characteristics and hemodynamics at baseline
The present study included 50 (61.7%) females and 31 (38.3%) males
with a mean age of 51 ± 18 years. The mean observation period was
46 months. The clinical characteristics, laboratory data, echocardiograph-
ic parameters and hemodynamics in RHC of the enrolled patients are
summarized in Table 1. Pericardial effusion was observed in 20 patients
(27.0%). Mean pulmonary artery pressure was 48.7 ± 19.0 mm Hg
and pulmonary vascular resistance was 705.2 ± 488.4 dyn s/cm5 at
baseline.
Association between pericardial effusion and the WHO-FC
The presence of pericardial effusionwas strongly correlatedwith the
WHO-FC status (p = 0.02), and they showed multicollinearity as
demonstrated by Cochran–Armitage test. The numbers of patients
with WHO-FCS I, II, III, and IV with pericardial effusion were 0, 1, 12,
and 3, respectively.
Predictors of mortality
A total of 29 (35.8%) patients diedduring the observation period. The
most frequent cause of death was right heart failure (n= 24), followed
by pneumonia (n = 3), interstitial pneumonia (n = 1) and sudden
death (n = 1). The one-, three- and ﬁve-year survival rates were esti-
mated to be 88.8%, 75.9% and 67.4%, respectively. The patients with
CHD-PAH had a better prognosis than those with other causes, and
their one-, three- and ﬁve-year survival rates were estimated to be
93.8% respectively (Fig. 1).
In the univariate Cox regression analysis,WHO-FCS III & IV, a cardiac
index (CI) b2.5 L/min/m2, and the presence of pericardial effusion at
baseline were signiﬁcantly associated with mortality. The multivariate
Cox proportional hazards analysis, which included the presence of
pericardial effusion as an independent variable, showed that the pres-
ence of pericardial effusion (HR 3.31, 95% CI 1.03–10.63, p = 0.04)
and mRAP ≥ 10 mm Hg (HR 3.19, 95% CI 1.03–9.83, p = 0.04) was
signiﬁcantly associated with all-cause death (Table 2). The age, PVR,
and CIwere not associatedwithmortality.WhenWHO-FCwas included
inmultivariate Cox hazard analysis instead of the presence of pericardi-
al effusion, only CI b 2.5 L/min/m2 (HR 3.89, 95% CI 1.05–14.45, p =
004) was associated with mortality (Table 3).
Pericardial effusion, etiology of PAH, and mortality
We also examined whether or not the presence of pericardial effu-
sion was a predictor of mortality in each PAH etiology. In the IPAH
group, patients with pericardial effusion had a poor prognosis (HR
3.36, 95% CI 1.08–10.43, p = 0.04). In comparison, the presence of
Table 1
Patient characteristics and hemodynamics at baseline.
Variables Mean ± SD or
25–75th percentile
Age (years) 51.1 ± 18.4
Gender Female 50 (61.7%)
Body mass index (kg/m2) 21.7 ± 4.3




Cause of PAH Idiopathic 34 (42.0%)
Connective tissue disease 28 (34.6%)
Congenital heart disease 16 (19.7%)
Others 3 (3.7%)
Therapy Monotherapy 26 (32.5%)
Combination therapy 50 (62.5%)
No PAH-speciﬁc therapy 4 (5.0%)




Combination therapy n (%) PGI2 + ERA + PDE-5 13 (26.0%)
PGI2 + ERA 12 (24.0%)
ERA + PDE-5 9 (18.0%)
PGI2 + ERA + PDE-5 + Epo 8 (16.0%)
Others 8 (16.0%)
Concomitant medication n (%) Warfarin 23 (29.5%)
Diuretics 33 (47.8%)
Digitalis 14 (17.9%)
Predonizolone monotherapy 12 (42.8% of CTD-PAH)
Immunosuppressor monotherapy 2 (7.1% of CTD-PAH)
Predonizolone and immunosuppressors 4 (14.3% of CTD-PAH)
Systolic blood pressure (mm Hg) 117 ± 23
Heart rate (bpm) 86 ± 14
Blood test BNP (pg/mL) 165.0 (60.7–419.7)
Uric acid (mg/dL) 6.6 (5.2–8.4)
eGFR (mL/min/1.73 m2) 71.2 ± 28.3
Parameter of right heart catheterization Mean pulmonary arterial pressure (mm Hg) 48.7 ± 19.0
Cardiac index (L/min/m2) 3.3 ± 1.6
Mean right atrial pressure (mm Hg) 10.2 ± 7.3
Pulmonary vascular resistance (dyn s/cm5) 705.2 ± 488.4
Parameter of echocardiogram Tricuspid regurgitation pressure gradient (mm Hg) 56.6 ± 23.2
Presence of pericardial effusion n (%) 20 (27.0%)
SD: standard deviation; WHO: World Health Organization; PAH: pulmonary arterial hypertension; ERA: endothelin receptor antagonists; PGI2: prostaglandin I2 analogs; PDE-5:
phosphodiesterase-5 inhibitors; Epo: epoprostenol; BNP: brain natriuretic peptide; eGFR: estimated glomerular ﬁltration rate.
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group (HR 0.51, 95% CI 0.06–4.48, p = 0.51) (Table 4).
Association between the presence of pericardial effusion and the
mRAP levels
Therewas a signiﬁcant association between themRAP levels and the
presence of pericardial effusion. Pericardial effusion was observed in
55.0% of PAH patients with a mRAP ≥ 11 mm Hg. On the other hand,
pericardial effusion was observed in only 17.4% of the patients with a
mRAP b 6 mm Hg (p = 0.01).
Association between one-year mortality and the mRAP levels
The one-year mortality rate in the present study was slightly higher
than that in the reports from the USA and Europe. Therefore, we exam-
ined the factors associatedwith the one-yearmortality. None of the PAH
patients whose mRAP was below themedian value of b 10mmHg died
within one year of the diagnosis, while 20.0% of the PAH patients with a
value of≥ 10mmHg died within one year (p= 0.02). Moreover, in the
group of patients with a mRAP≥ 10mmHg, the time from the onset of
symptoms to the diagnosis was signiﬁcantly longer than that in the
group of patients with a mRAP b 10 mm Hg (Welch test p = 0.03).Discussion
Themain ﬁndings of the present studywere: 1. The ﬁve-year surviv-
al rate of PAH patients was estimated to be 67.4%. As reference, the ﬁve-
year survival rate was 42.5% in IPAH in the previous report published in
1991 (Dalonzo et al., 1991). 2. The prognosis was better in the CTD-PAH
group than in the IPAH group. 3. The presence of pericardial effusion at
the time of the initial examination was an independent predictor of
mortality. When patients were stratiﬁed by the underlying diseases,
the presence of pericardial effusion was a signiﬁcant predictive factor
for IPAH cases, but no statistically signiﬁcant difference was observed
for CTD-PAH cases. 4. A mRAP level of ≥10 mm Hg at baseline was an
independent predictor of mortality and signiﬁcantly associated with
mortality at one year from the PAH diagnosis. Further, the period from
the onset of symptoms to the diagnosis was signiﬁcantly longer in
individuals with a mRAP of ≥10 mm Hg compared to that in patients
with a mRAP of b10 mm Hg. 5. CI b 2.5 L/min/m2 was associated with
mortality.
Since 1999, various therapeutic agents for PAH, including epopros-
tenol, oral prostaglandin I2 (PGI2) analogs, endothelin receptor antago-
nists (ERA), and phosphodiesterase-5 (PDE-5) inhibitors have become
available in Japan, and the results here support their usefulness. How-
ever, compared to the outcomes in the U.S.A. and Europe, the survival






































Fig. 1. The estimated survival rate of one-, three- and ﬁve-year in each PAH etiology.
407S. Adachi et al. / Life Sciences 118 (2014) 404–409factors related to mortality and the aggravation of symptoms in our
Japanese patients.
Patients with CTD-PAH usually have a poorer prognosis than those
with IPAH. In this study, the prognosis of CTD-PAH patients was not so
bad, which may be because the present patients were treated in fewTable 2
The univariate and multivariate hazards ratios among PAH patients.
Variables Univariate
HR 95% CI
Age (10-year increases) 1.25 0.99–1.59
Gender (female) 0.96 0.44–2.09
Body mass index
b21 kg/m2 1.58 0.67–3.75
WHO-FC
III & IV 12.54 1.69–93.07
eGFR
b45 mL/min/1.73 m2 0.85 0.20–3.67
Uric acid
≥7 mg/dL 1.21 0.50–2.96
BNP
≥170 pg/mL 1.26 0.49–3.28
Resting BPs (10 mm Hg increases) 0.94 0.80–1.09
Resting HR
≥80/min 0.85 0.35–2.04
Combination therapy 0.98 0.45–2.13
mPAP
≥50 mm Hg 1.38 0.60–3.19
CI
b2.5 L/min/m2 2.78 0.93–8.36
mRAP
≥10 mm Hg 2.46 0.91–6.66
PVR
≥520 dyn s/cm5 1.86 0.83–4.15
TRPG
≥50 mm Hg 1.96 0.73–5.26
Presence of pericardial effusion 3.33 1.44–7.68
95% CI: 95% conﬁdence intervals; HR: hazard ratios; BMI: body mass index: WHO-FC: World H
natriuretic peptide; BPs: systolic blood pressure; HR: heart rate; mPAP: mean pulmonary arteri
resistance; TRPG: tricuspid regurgitation pressure gradient.facilities that specialize in CTD, and there were fewer cases of severe
CTD compared to other studies.
It has been known that the presence of pericardial effusion at the
time of the initial examination, as well as the WHO-FC, is a predictive
factor for the outcome (Benza et al., 2010; Batal et al., 2012; RaymondMultivariate













0.08 3.19 1.03–9.83 0.04
0.13
0.18
0.01 3.31 1.03-10.63 0.04
ealth Organization functional class; eGFR: estimated glomerular ﬁltration rate; BNP: brain
al pressure; CI: cardiac index; mRAP: mean right atrial pressure; PVR: pulmonary vascular
Table 3
The univariate and multivariate hazards ratios among PAH patients (WHO-FC including model).
Variables Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age (10-year increases) 1.25 0.99–1.59 0.06
Gender (female) 0.96 0.44–2.09 0.92
Body mass index
b21 kg/m2 1.58 0.67–3.75 0.30
WHO-FC
III & IV 12.54 1.69–93.07 0.014
eGFR
b45 mL/min/1.73 m2 0.85 0.20–3.67 0.83
Uric acid
≥7 mg/dL 1.21 0.50–2.96 0.67
BNP
≥170 pg/mL 1.26 0.49–3.28 0.63
Resting BPs (10 mm Hg increases) 0.94 0.80–1.09 0.40
Resting HR
≥80/min 0.85 0.35–2.04 0.71
Combination therapy 0.98 0.45–2.13 0.96
mPAP
≥50 mm Hg 1.38 0.60–3.19 0.45
CI
b2.5 L/min/m2 2.78 0.93–8.36 0.07 3.89 1.05–14.45 0.04
mRAP
≥10 mm Hg 2.46 0.91–6.66 0.08
PVR
≥520 dyn s/cm5 1.86 0.83–4.15 0.13
TRPG
≥50 mm Hg 1.96 0.73–5.26 0.18
Presence of pericardial effusion 3.33 1.44–7.68 0.01
95% CI: 95% conﬁdence intervals; HR: hazard ratios; BMI: body mass index: WHO-FC: World Health Organization functional class; eGFR: estimated glomerular ﬁltration rate; BNP: brain
natriuretic peptide; BPs: systolic blood pressure; HR: heart rate; mPAP: mean pulmonary arterial pressure; CI: cardiac index; mRAP: mean right atrial pressure; PVR: pulmonary vascular
resistance; TRPG: tricuspid regurgitation pressure gradient.
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1989; Hinderliter et al., 1999). Although the WHO-FC is a very
useful prognostic factor (Humbert et al., 2010; Benza et al., 2010;
McLaughlin et al., 2002; Nickel et al., 2012), it is difﬁcult for physicians
who do not specialize in PAH treatment to judge the degree clearly
(Taichman et al., 2009). In the present study, we could not evaluate
both WHO-FC and presence of pericardial effusion at the same time,
because of their multicollinearity. The results of the present study
indicated that the presence of pericardial effusion and mRAP are strong
predictors of mortality in PAH patients in the analysis when WHO-FC
was excluded. However, a multivariate Cox hazards analysis including
WHO-FC instead of the presence of pericardial effusion revealed that
CI was an independent predictor of mortality. The result may indicate
that impaired cardiac function, which manifests as a reduced CI,
would affect physical activity in PAH patients.
The detailed mechanism underlying the development of pericardial
effusion in severe PAH patients remains unclear. The following mecha-
nisms have been suggested: Pericardial effusion is known to ﬂow back
into the right atrium through lymph and venous drainage. However,
when right atrial pressure increases, this backﬂow is limited, and this
may cause pericardial effusion (Miller et al., 1971; Natanzon and
Kronzon, 2009). Indeed, the size of pericardial effusion was reportedly
associated with the mRAP (Hinderliter et al., 1999). Accordingly, peri-
cardial effusion is suggestive of an increased right atrial pressure. InTable 4
The hazard ratio of pericardial effusion in PAH etiology.
HR 95% CI p value
IPAH 3.36 1.08–10.43 0.036
CTD-PAH 0.51 0.06–4.48 0.51
HR: hazard ratios; 95% CI: 95% conﬁdence intervals; IPAH: idiopathic pulmonary arterial
hypertension; CTD-PAH: connective tissue disease-associated pulmonary arterial
hypertension.the present study, the presence of pericardial effusion predicted the
prognosis in patients with IPAH, but not CTD-PAH. Several previous
reports have indicated that the presence of pericardial effusion is one
of the factors predicting a poor prognosis in the CTD-PAH group
(Ngian et al., 2012). However, unlike previous studies, pericardial effu-
sion due to pericarditis and serositis were not excluded from our
study, which may be the reason the presence of pericardial effusion
was not a predictive factor in the CTD-PAH patients in our study. More-
over, Fenstad et al. reported that the presence and degree of pericardial
effusion were signiﬁcantly associated with connective tissue disease,
and 21.5% of IPAH and 45.9% of CTD-PAH had a pericardial effusion
(Fenstad et al., 2013). Similarly, Luo et al. reported that 39.3% of PAH pa-
tients had pericardial effusion (Luo et al., 2011). Their study population
might containmore severe CTD-PAH patients compared to our study, in
which only 21.4% of CTD-PAH patients had pericardial effusion.
A high mRAP value at the time of the initial examination was an in-
dependent predictor of mortality. Furthermore, it tended to be associat-
ed with a poor prognosis within one year. If we consider that most PAH
cases ultimately die after right ventricular failure occurs, a high mRAP,
an indicator of a reduced right ventricular function, would be a predic-
tive factor for the short-term deterioration of the prognosis. Previous
studies have indicated that the presence of pericardial effusion is associ-
ated with RV impairment (Frohlich et al., 2013), and that the mRAP is
associated with the right ventricular ﬁlling pressure (Natanzon and
Kronzon, 2009). Thus, an elevated mRAP level is suggestive of right
heart failure in PAH, and would logically be a predictor of a poor prog-
nosis. In this study, the right ventricular systolic function, such as tri-
cuspid annular plane systolic excursion (TAPSE), was not measured.
Therefore, further studies are needed to assess the relationship between
the mRAP and the right ventricular function.
The limitations of the present study must be mentioned. First, the
present study was only conducted in a speciﬁc region in Japan. There-
fore, our results may not be generalized to all patients with group 1 &
1′ PAH of Dana Point classiﬁcation. Second, our sample size was small,
409S. Adachi et al. / Life Sciences 118 (2014) 404–409and the number of events was limited. Third, this was a retrospective
study in which the usage of medication was not consistent. Fourth,
the volume of pericardial effusion was not quantitatively measured
and inter- and intra-observer variability was not assessed. However,
the presence of pericardial effusion was determined by at least one
sonographer and two cardiologists. Fifth, right heart function was not
routinely recorded in detail back then. Nonetheless, the results of this
study were based on the actual conditions in everyday clinical practice
in Japan, and should be useful for guiding practice in Japan in the current
era.
Conclusion
The mortality rate of the patients with group 1 & 1′ PAH of Dana
Point classiﬁcation was slightly higher in our study than the rates in
the U.S.A. and Europe reports under the contemporary PAH treatment.
The presence of pericardial effusion and mRAP, or CI b 2.5 L/min/m2
was found to be independent predictors of mortality. The presence
of pericardial effusion could be a useful marker that can be used as a
supplement to the WHO-FC.
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